End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
3.51 USD | -3.04% | -13.44% | +97.19% |
May. 10 | ProKidney Q1 Loss Unchanged From Year Earlier | MT |
May. 10 | ProKidney Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Capitalization 1 | 422.2 | 119.5 | 215.4 | - | - |
Enterprise Value (EV) 1 | -68.09 | 119.5 | 22.53 | -95 | -82.7 |
P/E ratio | -29.8 x | -3.12 x | -2.64 x | -4.7 x | -4.65 x |
Yield | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - |
EV / Revenue | - | - | - | - | - |
EV / EBITDA | 0.45 x | -0.81 x | -0.14 x | 0.45 x | 0.33 x |
EV / FCF | 0.86 x | - | -0.22 x | 0.29 x | 0.26 x |
FCF Yield | 116% | - | -448% | 347% | 388% |
Price to Book | -1.46 x | - | -0.41 x | -1.06 x | 3.12 x |
Nbr of stocks (in thousands) | 61,540 | 67,137 | 63,923 | - | - |
Reference price 2 | 6.860 | 1.780 | 3.370 | 3.370 | 3.370 |
Announcement Date | 3/28/23 | 3/22/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - |
EBITDA 1 | -150 | -147.7 | -166.9 | -210.5 | -247.2 |
EBIT 1 | -153 | -151.5 | -170.6 | -210.8 | -244.3 |
Operating Margin | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -147.2 | -159.5 | -162.6 | -207.4 | -234.6 |
Net income 1 | -108 | -35.47 | -145.9 | -43.72 | -51.84 |
Net margin | - | - | - | - | - |
EPS 2 | -0.2300 | -0.5700 | -1.278 | -0.7168 | -0.7254 |
Free Cash Flow 1 | -78.94 | - | -101 | -330 | -321 |
FCF margin | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share 2 | - | - | - | - | - |
Announcement Date | 3/28/23 | 3/22/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA 1 | -34.79 | -29.44 | - | - | - | -23.06 | -38.97 | -39.08 | -44.86 | -45.55 | - | - |
EBIT 1 | -35.57 | -30.24 | -40.88 | -39.82 | -46.62 | -24.21 | -40.08 | -41.66 | -46.26 | -47.92 | - | - |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -25.84 | - | -33.86 | -41.08 | -18.93 | -35.24 | -39.01 | -42.45 | -45.91 | - | - |
Net income 1 | -11.93 | -6.487 | -9.665 | -9.118 | -10.98 | -5.701 | -9.492 | -35.64 | -36.88 | -38.15 | - | - |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.1300 | -0.1100 | - | -0.1400 | -0.1800 | -0.0900 | -0.1600 | -0.3216 | -0.3398 | -0.3347 | - | - |
Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/14/22 | 3/28/23 | 5/11/23 | 8/10/23 | 11/14/23 | 3/22/24 | 5/10/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - |
Net Cash position 1 | 490 | - | 193 | 310 | 298 |
Leverage (Debt/EBITDA) | - | - | - | - | - |
Free Cash Flow 1 | -78.9 | - | -101 | -330 | -321 |
ROE (net income / shareholders' equity) | - | - | -50% | -55.5% | -51.6% |
ROA (Net income/ Total Assets) | - | - | - | - | - |
Assets 1 | - | - | - | - | - |
Book Value Per Share 2 | -4.700 | - | -8.240 | -3.160 | 1.080 |
Cash Flow per Share 2 | -1.250 | - | -0.5600 | -0.5600 | - |
Capex 1 | 1.85 | - | 50 | 200 | 200 |
Capex / Sales | - | - | - | - | - |
Announcement Date | 3/28/23 | 3/22/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+97.19% | 224M | |
+67.53% | 62.86B | |
-0.77% | 41.38B | |
+45.66% | 40.38B | |
-10.72% | 27.64B | |
+13.30% | 26.46B | |
-22.79% | 18.9B | |
+4.70% | 12.67B | |
+24.10% | 12.27B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- PROK Stock
- Financials ProKidney Corp.